NEW YORK (GenomeWeb News) — Innogenetics today said that a US District Court in Wisconsin has barred Abbott Laboratories from using or selling its hepatitis C genotyping technology anywhere in the world after an earlier verdict found Abbott to infringe a US patent held by Innogenetics.
Innogenetics sued Abbott Laboratories in 2005 for infringing US Patent No. 5,846,704. In September 2006 a jury awarded Innogenetics $7 million, and last week the judge in the case upheld that award, denied Abbott a new trial on “infringement and validity,” and set the date to consider barring Abbott permanently from selling the infringing products.
Innogenetics also sued Third Wave Technologies for allegedly infringing the same IP, but Third Wave settled the case under a non-exclusive licensing agreement and optional extension with Innogenetics.